Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s65, 2022. DOI: 10.25251/skin.6.supp.65. Disponível em: https://skin.dermsquared.com/skin/article/view/1820. Acesso em: 1 may. 2026.